Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

By G. Draisma, Ruth Etzioni, A. Tsodikov, A. Mariotto, E. Wever, R. Gulati, E. Feuer, H. D. de Koning. Journal of the National Cancer Institute, 2009

817 citations recorded by the source corpus.

Subfields: Oncology, Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/61b2637d1832dd089f56ebacc291863d7ee8a6ba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Public Health, Environmental and Occupational Health

In Pulmonary and Respiratory Medicine

Citations in the corpus

Cancer statistics, 2016 (2016, background): “Routine screening with the PSA test is no longer recommended because of growing concerns about high rates of overdiagnosis, estimated at 23% to 42% for screen-detected cancers.(27,28) Despite declines in the prevalence of PSA screening from 2010 to 2013, one-third of men aged 65 years and older with”
International variation in prostate cancer incidence and mortality rates. (2012, neutral): “It has been estimated that 23–42% of PCa cases in Europe and the United States result from overdiagnosis due to PSA testing [32] [33].”
Epidemiology of Prostate Cancer (2019, neutral): “According to recently conducted research studies, around 20-40% of the prostate cancer cases in the USA and Europe could be due to overdiagnosis through extensive PSA testing [12, 15, 16].”
Cancer statistics, 2015 (2015, background): “Routine screening with the PSA test is no longer recommended because of growing concerns about high rates of overdiagnosis, estimated at 23% to 42% for screen-detected cancers.(36) PSA testing rates may have declined in recent years among men aged younger than 50 years, as well as in those aged 75 y”
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. (2012, background): “Thus, a higher percentage of deaths from other causes rather than a deficit occurred among the prostate cancer patients diagnosed in the intervention arm, an indication of the overdiagnosis associated with PSA screen detection (14).”
Global Cancer Incidence and Mortality Rates and Trends—An Update (2015, neutral): “Routine screening using PSA testing is no longer recommended for men at average risk, as overdiagnosis is estimated to account for 23% to 42% of screendetected cancers (48), and the side effects of treatment are often serious.”
Global cancer statistics, 2012 (2015, background): “Routine PSA screening is no longer recommended for men at average risk given the large potential for serious side effects associated with prostate cancer treatment and concerns about frequent overdiagnosis, estimated at 23% to 42% for screen-detected cancers.(69) Studies are underway to evaluate new”
Overdiagnosis and Overtreatment of Prostate Cancer (2014, methodology): “Disease modeling studies based on US incidence trends have estimated that 22% [7] to 42% [17] of screen-detected cases of PCa in the United States are overdiagnosed.”